Ordering PathVysion From Your Lab
HER-2 status assessment is now a standard of care in the selection of therapy for invasive breast cancer.1
Some laboratories continue to use IHC to assess HER-2 status.2 To ensure your patient’s HER-2 status is determined by a FISH-based method, ask for PathVysion , specifically, on the laboratory requisition form.
1 NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, V.2, 2010, www.nccn.org
2 Allison M, The HER2 testing conundrum. Nature Biotechnology 28 (2): 117-119, 2010.
